{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:00:43Z","timestamp":1793336443514,"version":"4.5.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T00:00:00Z","timestamp":1701907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T00:00:00Z","timestamp":1701907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Colorectal cancer (CRC), the third most common cancer worldwide, remains highly lethal as the disease only becomes symptomatic at an advanced stage. Growing evidence suggests that histone deacetylases (HDACs), a group of epigenetic enzymes overexpressed in precancerous lesions of CRC, may represent promising molecular targets for CRC treatment. Histone deacetylase inhibitors (HDACis) have gradually become powerful anti-cancer agents targeting epigenetic modulation and have been widely used in the clinical treatment of hematologic malignancies, while only few studies on the benefit of HDACis in the treatment of CRC. In the present study, we designed a series of small-molecule Thiazole-based HDACis, among which HR488B bound to HDAC1 with a high affinity and exerted effective anti-CRC activity both in vitro and in vivo. Moreover, we revealed that HR488B specifically suppressed the growth of CRC cells by inducing cell cycle G0\/G1 arrest and apoptosis via causing mitochondrial dysfunction, reactive oxygen species (ROS) generation, and DNA damage accumulation. Importantly, we noticed that HR488B significantly decreased the expression of the E2F transcription factor 1 (E2F1), which was crucial for the inhibitory effect of HR488B on CRC. Mechanistically, HR488B obviously decreased the phosphorylation level of the retinoblastoma protein (Rb), and subsequently prevented the release of E2F1 from the E2F1\/Rb\/HDAC1 complex, which ultimately suppressed the growth of CRC cells. Overall, our study suggests that HR488B, a novel and efficient HDAC1 inhibitor, may be a potential candidate for CRC therapy in the future. Furthermore, targeting the E2F1\/Rb\/HDAC1 axis with HR488B provides a promising therapeutic avenue for CRC.<\/jats:p>","DOI":"10.1038\/s41419-023-06205-0","type":"journal-article","created":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T19:02:33Z","timestamp":1701975753000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Targeting the E2F1\/Rb\/HDAC1 axis with the small molecule HR488B effectively inhibits colorectal cancer growth"],"prefix":"10.1038","volume":"14","author":[{"given":"Namin","family":"Duan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiran","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuru","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxia","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8503-9868","authenticated-orcid":false,"given":"Wenhui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feifei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7009-9187","authenticated-orcid":false,"given":"Ning","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,7]]},"reference":[{"key":"6205_CR1","first-page":"1","volume":"0","author":"E Morgan","year":"2022","unstructured":"Morgan E, Arnold M, Gini A, Lorenzoni V, Cabasag CJ, Laversanne M, et al. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut. 2022;0:1\u20137.","journal-title":"Gut"},{"key":"6205_CR2","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/S0140-6736(19)32319-0","volume":"394","author":"E Dekker","year":"2019","unstructured":"Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet. 2019;394:1467\u201380.","journal-title":"Lancet"},{"key":"6205_CR3","first-page":"149","volume":"32","author":"G Fang","year":"2017","unstructured":"Fang G, Zheng W, Hang Y, Junxian Y, Bangwei C. Molecular targeted drugs and treatment of colorectal cancer: recent progress and future perspectives. Cancer Biother Radiopharm. 2017;32:149\u201360.","journal-title":"Cancer Biother Radiopharm"},{"key":"6205_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0776-6","volume":"9","author":"Q Wang","year":"2018","unstructured":"Wang Q, Shi Y, Zhou K, Wang L, Yan Z, Liu Y, et al. PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer. Cell Death Dis. 2018;9:739.","journal-title":"Cell Death Dis"},{"key":"6205_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/carcin\/bgp220","volume":"31","author":"S Sharma","year":"2010","unstructured":"Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis. 2010;31:27\u201336.","journal-title":"Carcinogenesis"},{"key":"6205_CR6","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd4360","volume":"13","author":"KJ Falkenberg","year":"2014","unstructured":"Falkenberg KJ, Johnstone RW. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov. 2014;13:673\u201391.","journal-title":"Nat Rev Drug Discov"},{"key":"6205_CR7","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41580-021-00441-y","volume":"23","author":"M Shvedunova","year":"2022","unstructured":"Shvedunova M, Akhtar A. Modulation of cellular processes by histone and non-histone protein acetylation. Nat Rev Mol Cell Biol. 2022;23:329\u201349.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"6205_CR8","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.2174\/0929867328666210915105929","volume":"29","author":"N Garmpis","year":"2022","unstructured":"Garmpis N, Damaskos C, Garmpi A, Nonni A, Georgakopoulou VE, Antoniou E, et al. Histone deacetylases and their inhibitors in colorectal cancer therapy: current evidence and future considerations. CMC. 2022;29:2979\u201394.","journal-title":"CMC"},{"key":"6205_CR9","doi-asserted-by":"publisher","first-page":"a026831","DOI":"10.1101\/cshperspect.a026831","volume":"6","author":"Y Li","year":"2016","unstructured":"Li Y, Seto E. HDACs and HDAC inhibitors in cancer development and therapy. Cold Spring Harb Perspect Med. 2016;6:a026831.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"6205_CR10","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1158\/1535-7163.MCT-21-0455","volume":"21","author":"JR Diamond","year":"2022","unstructured":"Diamond JR, Pitts TM, Ungermannova D, Nasveschuk CG, Zhang G, Phillips AJ, et al. Preclinical development of the class-I-selective histone deacetylase inhibitor OKI-179 for the treatment of solid tumors. Mol Cancer Ther. 2022;21:397\u2013406.","journal-title":"Mol Cancer Ther"},{"key":"6205_CR11","first-page":"757","volume":"10","author":"Z Fang","year":"2020","unstructured":"Fang Z, Lin M, Li C, Liu H, Gong C. A comprehensive review of the roles of E2F1 in colon cancer. Am J Cancer Res. 2020;10:757\u201368.","journal-title":"Am J Cancer Res"},{"key":"6205_CR12","doi-asserted-by":"publisher","first-page":"e970480","DOI":"10.4161\/23723548.2014.970480","volume":"2","author":"A Poppy Roworth","year":"2015","unstructured":"Poppy Roworth A, Ghari F, La Thangue NB. To live or let die - complexity within the E2F1 pathway. Mol Cell Oncol. 2015;2:e970480.","journal-title":"Mol Cell Oncol"},{"key":"6205_CR13","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1007\/s11033-021-06916-7","volume":"49","author":"H Xu","year":"2022","unstructured":"Xu H, Liang S, Hu J, Liu W, Dong Z, Wei S. Deltex E3 ubiquitin ligase 3 inhibits colorectal cancer cell growth and regulates cell cycle progression via upregulating E2F transcription factor 1. Mol Biol Rep. 2022;49:1661\u20138.","journal-title":"Mol Biol Rep"},{"key":"6205_CR14","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ymthe.2019.12.008","volume":"28","author":"C Zhou","year":"2020","unstructured":"Zhou C, Liu H, Wang F, Hu T, Liang Z, Lan N, et al. circCAMSAP1 promotes tumor growth in colorectal cancer via the miR-328-5p\/E2F1 axis. Mol Ther. 2020;28:914\u201328.","journal-title":"Mol Ther"},{"key":"6205_CR15","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s11658-022-00392-y","volume":"27","author":"Z Fang","year":"2022","unstructured":"Fang Z, Lin M, Chen S, Liu H, Zhu M, Hu Y, et al. E2F1 promotes cell cycle progression by stabilizing spindle fiber in colorectal cancer cells. Cell Mol Biol Lett. 2022;27:90.","journal-title":"Cell Mol Biol Lett"},{"key":"6205_CR16","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.cell.2005.09.044","volume":"123","author":"SM Rubin","year":"2005","unstructured":"Rubin SM, Gall A-L, Zheng N, Pavletich NP. Structure of the Rb C-terminal domain bound to E2F1-DP1: a mechanism for phosphorylation-induced E2F release. Cell. 2005;123:1093\u2013106.","journal-title":"Cell"},{"key":"6205_CR17","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.3390\/cancers12102807","volume":"12","author":"F Guzman","year":"2020","unstructured":"Guzman F, Fazeli Y, Khuu M, Salcido K, Singh S, Benavente CA. Retinoblastoma tumor suppressor protein roles in epigenetic regulation. Cancers. 2020;12:2807.","journal-title":"Cancers"},{"key":"6205_CR18","doi-asserted-by":"publisher","first-page":"5420","DOI":"10.1038\/sj.onc.1210610","volume":"26","author":"MA Glozak","year":"2007","unstructured":"Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene. 2007;26:5420\u201332.","journal-title":"Oncogene"},{"key":"6205_CR19","doi-asserted-by":"publisher","first-page":"234","DOI":"10.15252\/embr.201744046","volume":"19","author":"C Vuillier","year":"2018","unstructured":"Vuillier C, Lohard S, F\u00e9tiveau A, All\u00e8gre J, Kayaci C, King LE, et al. E2F1 interacts with BCL-XL and regulates its subcellular localization dynamics to trigger cell death. EMBO Rep. 2018;19:234\u201343.","journal-title":"EMBO Rep"},{"key":"6205_CR20","doi-asserted-by":"crossref","unstructured":"Zhao M, Liu Y, Chang J, Qi J, Liu R, Hou Y et al. ILF2 cooperates with E2F1 to maintain mitochondrial homeostasis and promote small cell lung cancer progression. Cancer Biol. Med. 2019;16:15.","DOI":"10.20892\/j.issn.2095-3941.2019.0050"},{"key":"6205_CR21","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/med.21320","volume":"35","author":"L Zhang","year":"2015","unstructured":"Zhang L, Han Y, Jiang Q, Wang C, Chen X, Li X, et al. Trend of histone deacetylase inhibitors in cancer therapy: isoform selectivity or multitargeted strategy: HISTONE DEACETYLASE INHIBITORS IN CANCER THERAPY. Med Res Rev. 2015;35:63\u201384.","journal-title":"Med Res Rev"},{"key":"6205_CR22","doi-asserted-by":"publisher","first-page":"3493","DOI":"10.7150\/ijbs.62339","volume":"17","author":"M Bai","year":"2021","unstructured":"Bai M, Cui M, Li M, Yao X, Wu Y, Zheng L, et al. Discovery of a novel HDACi structure that inhibits the proliferation of ovarian cancer cells in vivo and in vitro. Int J Biol Sci. 2021;17:3493\u2013507.","journal-title":"Int J Biol Sci"},{"key":"6205_CR23","doi-asserted-by":"publisher","first-page":"bbab098","DOI":"10.1093\/bib\/bbab098","volume":"22","author":"F Ahammad","year":"2021","unstructured":"Ahammad F, Alam R, Mahmud R, Akhter S, Talukder EK, Tonmoy AM, et al. Pharmacoinformatics and molecular dynamics simulation-based phytochemical screening of neem plant (Azadiractha indica) against human cancer by targeting MCM7 protein. Brief Bioinforma. 2021;22:bbab098.","journal-title":"Brief Bioinforma"},{"key":"6205_CR24","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/ncb1837","volume":"11","author":"YM Oh","year":"2009","unstructured":"Oh YM, Kwon YE, Kim JM, Bae SJ, Lee BK, Yoo SJ, et al. Chfr is linked to tumour metastasis through the downregulation of HDAC1. Nat Cell Biol. 2009;11:295\u2013302.","journal-title":"Nat Cell Biol"},{"key":"6205_CR25","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1111\/cas.12953","volume":"107","author":"K Mori","year":"2016","unstructured":"Mori K, Uchida T, Fukumura M, Tamiya S, Higurashi M, Sakai H, et al. Linkage of E2F1 transcriptional network and cell proliferation with respiratory chain activity in breast cancer cells. Cancer Sci. 2016;107:963\u201371.","journal-title":"Cancer Sci"},{"key":"6205_CR26","doi-asserted-by":"publisher","first-page":"e2570","DOI":"10.1038\/cddis.2016.465","volume":"8","author":"Y Wu","year":"2018","unstructured":"Wu Y, Ma S, Xia Y, Lu Y, Xiao S, Cao Y, et al. Loss of GCN5 leads to increased neuronal apoptosis by upregulating E2F1- and Egr-1-dependent BH3-only protein Bim. Cell Death Dis. 2018;8:e2570.","journal-title":"Cell Death Dis"},{"key":"6205_CR27","doi-asserted-by":"publisher","first-page":"36487","DOI":"10.1021\/acsami.2c12076","volume":"14","author":"J Yan","year":"2022","unstructured":"Yan J, Hanif S, Zhang D, Ismail M, Wang X, Li Q, et al. Arsenic prodrug-mediated tumor microenvironment modulation platform for synergetic glioblastoma therapy. ACS Appl Mater Interfaces. 2022;14:36487\u2013502.","journal-title":"ACS Appl Mater Interfaces"},{"key":"6205_CR28","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0092-8674(00)80564-4","volume":"96","author":"DL Vaux","year":"1999","unstructured":"Vaux DL, Korsmeyer SJ. Cell death in development. Cell. 1999;96:245\u201354.","journal-title":"Cell"},{"key":"6205_CR29","doi-asserted-by":"publisher","first-page":"558","DOI":"10.3390\/ijms17040558","volume":"17","author":"Y Ding","year":"2016","unstructured":"Ding Y, Wang H, Niu J, Luo M, Gou Y, Miao L, et al. Induction of ROS overload by alantolactone prompts oxidative DNA damage and apoptosis in colorectal cancer cells. IJMS. 2016;17:558.","journal-title":"IJMS"},{"key":"6205_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04783-z","volume":"13","author":"Y Chen","year":"2022","unstructured":"Chen Y, Feng X, Yuan Y, Jiang J, Zhang P, Zhang B. Identification of a novel mechanism for reversal of doxorubicin-induced chemotherapy resistance by TXNIP in triple-negative breast cancer via promoting reactive oxygen-mediated DNA damage. Cell Death Dis. 2022;13:338.","journal-title":"Cell Death Dis"},{"key":"6205_CR31","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1101\/gad.813200","volume":"14","author":"JW Harbour","year":"2000","unstructured":"Harbour JW, Dean DC. The Rb\/E2F pathway: expanding roles and emerging paradigms. Genes Dev. 2000;14:2393\u2013409.","journal-title":"Genes Dev"},{"key":"6205_CR32","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/35410","volume":"391","author":"L Magnaghi-Jaulin","year":"1998","unstructured":"Magnaghi-Jaulin L, Groisman R, Naguibneva I, Robin P, Lorain S, Le Villain JP, et al. Retinoblastoma protein represses transcription by recruiting a histone deacetylase. Nature. 1998;391:601\u20135.","journal-title":"Nature"},{"key":"6205_CR33","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA A Cancer J Clin. 2019;69:7\u201334.","journal-title":"CA A Cancer J Clin"},{"key":"6205_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.249","volume":"10","author":"X He","year":"2020","unstructured":"He X, Zhong X, Hu Z, Zhao S, Wei P, Li D. An insight into small extracellular vesicles: their roles in colorectal cancer progression and potential clinical applications. Clin Transl Med. 2020;10:e249.","journal-title":"Clin Transl Med"},{"key":"6205_CR35","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.bbrc.2015.06.103","volume":"464","author":"Z Fang","year":"2015","unstructured":"Fang Z, Gong C, Liu H, Zhang X, Mei L, Song M, et al. E2F1 promote the aggressiveness of human colorectal cancer by activating the ribonucleotide reductase small subunit M2. Biochem Biophys. Res Commun. 2015;464:407\u201315.","journal-title":"Biochem Biophys. Res Commun"},{"key":"6205_CR36","first-page":"567","volume":"53","author":"J Chen","year":"2018","unstructured":"Chen J, Gong C, Mao H, Li Z, Fang Z, Chen Q, et al. E2F1\/SP3\/STAT6 axis is required for IL-4-induced epithelial-mesenchymal transition of colorectal cancer cells. Int J Oncol. 2018;53:567\u201378.","journal-title":"Int J Oncol"},{"key":"6205_CR37","doi-asserted-by":"publisher","first-page":"188336","DOI":"10.1016\/j.bbcan.2019.188336","volume":"1873","author":"JN Chun","year":"2020","unstructured":"Chun JN, Cho M, Park S, So I, Jeon J-H. The conflicting role of E2F1 in prostate cancer: a matter of cell context or interpretational flexibility? Biochim. Biophys. Acta (BBA) - Rev Cancer. 2020;1873:188336.","journal-title":"Biochim. Biophys. Acta (BBA) - Rev Cancer"},{"key":"6205_CR38","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.molmed.2012.10.009","volume":"19","author":"BM P\u00fctzer","year":"2013","unstructured":"P\u00fctzer BM, Engelmann D. E2F1 apoptosis counterattacked: evil strikes back. Trends Mol Med. 2013;19:89\u201398.","journal-title":"Trends Mol Med"},{"key":"6205_CR39","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.cell.2016.07.002","volume":"166","author":"S Vyas","year":"2016","unstructured":"Vyas S, Zaganjor E, Haigis MC. Mitochondria and cancer. Cell. 2016;166:555\u201366.","journal-title":"Cell"},{"key":"6205_CR40","doi-asserted-by":"crossref","unstructured":"Estaquier J, Vallette F, Vayssiere J-L, Mignotte B. The mitochondrial pathways of apoptosis. In: Scatena R, Bottoni P, Giardina B, editors. Advances in mitochondrial medicine, Vol. 942. Dordrecht: Springer Netherlands; 2012. p. 157\u201383.","DOI":"10.1007\/978-94-007-2869-1_7"},{"key":"6205_CR41","doi-asserted-by":"publisher","first-page":"764699","DOI":"10.3389\/fphar.2021.764699","volume":"12","author":"S Yan","year":"2022","unstructured":"Yan S, Zhang B, Feng J, Wu H, Duan N, Zhu Y, et al. FGFC1 Selectively Inhibits Erlotinib-Resistant Non-Small Cell Lung Cancer via Elevation of ROS Mediated by the EGFR\/PI3K\/Akt\/mTOR Pathway. Front Pharm. 2022;12:764699.","journal-title":"Front Pharm"},{"key":"6205_CR42","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1038\/ncb2309","volume":"13","author":"E Blanchet","year":"2011","unstructured":"Blanchet E, Annicotte J-S, Lagarrigue S, Aguilar V, Clap\u00e9 C, Chavey C, et al. E2F transcription factor-1 regulates oxidative metabolism. Nat Cell Biol. 2011;13:1146\u201352.","journal-title":"Nat Cell Biol"},{"key":"6205_CR43","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.freeradbiomed.2009.12.022","volume":"48","author":"ML Circu","year":"2010","unstructured":"Circu ML, Aw TY. Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic Biol Med. 2010;48:749\u201362.","journal-title":"Free Radic Biol Med"},{"key":"6205_CR44","first-page":"1","volume":"51","author":"E-H Choi","year":"2019","unstructured":"Choi E-H, Kim KP. E2F1 facilitates DNA break repair by localizing to break sites and enhancing the expression of homologous recombination factors. Exp Mol Med. 2019;51:1\u201312.","journal-title":"Exp Mol Med"},{"key":"6205_CR45","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/S0092-8674(00)81589-5","volume":"94","author":"X Luo","year":"1998","unstructured":"Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell. 1998;94:481\u201390.","journal-title":"Cell"},{"key":"6205_CR46","doi-asserted-by":"publisher","first-page":"4166","DOI":"10.1073\/pnas.0809645106","volume":"106","author":"PJ Day","year":"2009","unstructured":"Day PJ, Cleasby A, Tickle IJ, O\u2019Reilly M, Coyle JE, Holding FP, et al. Crystal structure of human CDK4 in complex with a D-type cyclin. Proc Natl Acad Sci USA. 2009;106:4166\u201370.","journal-title":"Proc Natl Acad Sci USA"},{"key":"6205_CR47","doi-asserted-by":"publisher","first-page":"e11208","DOI":"10.1371\/journal.pone.0011208","volume":"5","author":"SK Kachhap","year":"2010","unstructured":"Kachhap SK, Rosmus N, Collis SJ, Kortenhorst MSQ, Wissing MD, Hedayati M, et al. Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor. PLoS ONE. 2010;5:e11208.","journal-title":"PLoS ONE"},{"key":"6205_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12861-8","volume":"10","author":"S Manickavinayaham","year":"2019","unstructured":"Manickavinayaham S, V\u00e9lez-Cruz R, Biswas AK, Bedford E, Klein BJ, Kutateladze TG, et al. E2F1 acetylation directs p300\/CBP-mediated histone acetylation at DNA double-strand breaks to facilitate repair. Nat Commun. 2019;10:4951.","journal-title":"Nat Commun"},{"key":"6205_CR49","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.canlet.2018.05.032","volume":"431","author":"S-Z Li","year":"2018","unstructured":"Li S-Z, Zeng F, Li J, Shu Q-P, Zhang H-H, Xu J, et al. Nemo-like kinase (NLK) primes colorectal cancer progression by releasing the E2F1 complex from HDAC1. Cancer Lett. 2018;431:43\u201353.","journal-title":"Cancer Lett"},{"key":"6205_CR50","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/cas.15183","volume":"113","author":"HS Yun","year":"2022","unstructured":"Yun HS, Lee J, Kim J, Sim Y, Lee C, Park JK, et al. A novel function of HRP-3 in regulating cell cycle progression via the HDAC-E2F1-Cyclin E pathway in lung cancer. Cancer Sci. 2022;113:145\u201355.","journal-title":"Cancer Sci"},{"key":"6205_CR51","doi-asserted-by":"publisher","first-page":"e12417","DOI":"10.1371\/journal.pone.0012417","volume":"5","author":"Y-A Tang","year":"2010","unstructured":"Tang Y-A, Wen W-L, Chang J-W, Wei T-T, Tan Y-HC, Salunke S, et al. A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer. PLoS ONE. 2010;5:e12417.","journal-title":"PLoS ONE"},{"key":"6205_CR52","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ejmech.2018.12.039","volume":"164","author":"S Banerjee","year":"2019","unstructured":"Banerjee S, Adhikari N, Amin SA, Jha T. Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: an overview. Eur J Medicinal Chem. 2019;164:214\u201340.","journal-title":"Eur J Medicinal Chem"},{"key":"6205_CR53","doi-asserted-by":"publisher","first-page":"8693","DOI":"10.1093\/nar\/gkw549","volume":"44","author":"N Liu","year":"2016","unstructured":"Liu N, Ding D, Hao W, Yang F, Wu X, Wang M, et al. hTERT promotes tumor angiogenesis by activating VEGF via interactions with the Sp1 transcription factor. Nucleic Acids Res. 2016;44:8693\u2013703.","journal-title":"Nucleic Acids Res"},{"key":"6205_CR54","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/jcc.21256","volume":"30","author":"GM Morris","year":"2009","unstructured":"Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem. 2009;30:2785\u201391.","journal-title":"J Comput Chem"},{"key":"6205_CR55","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/nprot.2016.051","volume":"11","author":"S Forli","year":"2016","unstructured":"Forli S, Huey R, Pique ME, Sanner MF, Goodsell DS, Olson AJ. Computational protein-ligand docking and virtual drug screening with the AutoDock suite. Nat Protoc. 2016;11:905\u201319.","journal-title":"Nat Protoc"},{"key":"6205_CR56","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1002\/jcc.20035","volume":"25","author":"J Wang","year":"2004","unstructured":"Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA. Development and testing of a general amber force field. J Comput Chem. 2004;25:1157\u201374.","journal-title":"J Comput Chem"},{"key":"6205_CR57","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3390\/md20010076","volume":"20","author":"J Feng","year":"2022","unstructured":"Feng J, Li S, Zhang B, Duan N, Zhou R, Yan S, et al. FGFC1 exhibits anti-cancer activity via inhibiting NF-\u03baB signaling pathway in EGFR-mutant NSCLC cells. Mar Drugs. 2022;20:76.","journal-title":"Mar Drugs"},{"key":"6205_CR58","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/cr.2013.42","volume":"23","author":"R Wang","year":"2013","unstructured":"Wang R, Wang Y, Liu N, Ren C, Jiang C, Zhang K, et al. FBW7 regulates endothelial functions by targeting KLF2 for ubiquitination and degradation. Cell Res. 2013;23:803\u201319.","journal-title":"Cell Res"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06205-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06205-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06205-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T19:04:12Z","timestamp":1701975852000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06205-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,7]]},"references-count":58,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["6205"],"URL":"https:\/\/doi.org\/10.1038\/s41419-023-06205-0","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,7]]},"assertion":[{"value":"15 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The animal use and experimental procedures were approved by the Institutional Animal Care and Use Committee of Shanghai Ocean University (Shanghai, China).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"801"}}